CARL vs ZBH
CARL: Carlsmed is a medical technology company revolutionizing spinal surgery with AI-enabled, patient-specific implants that improve outcomes and surgical precision. ZBH: A global medical device company focused on musculoskeletal healthcare, including orthopedic implants and advanced surgical technologies.
Side-by-side fundamentals
| Metric | CARL | ZBH | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $14.31 | $94.86 | |
| Market cap | $391M | $18.1B | |
| P/E as of 2026-10-21 | n/a | 23.02 | |
| Net margin FY2025, SEC XBRL | n/a | +8.6% | |
| Operating margin FY2025, SEC XBRL | n/a | +13.3% | |
| ROE FY2025, SEC XBRL | -30.0% | +5.5% | ZBH higher |
| ROA FY2025, SEC XBRL | -22.8% | +3.1% | ZBH higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.18 | 0.59 | CARL lower |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +7.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +5.9% | |
| Dividend yield as of 2026-09-02 | n/a | +1.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 15 | ZBH higher |
| Beta as of 2026-09-03 | 1.26 | 0.28 | |
| 1-year return as of 2026-10-21 close | +1.5% | -7.6% | CARL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.